Plasma generated ozone and reactive oxygen species for point of use PPE decontamination system

Hygiene requirements for cleaning and disinfection of surfaces: recommendation of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute

This recommendation of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) addresses not only hospitals, but also outpatient health care facilities and compiles current evidence. The following criteria are the basis for the indications for cleaning and disinfection: Infectious bioburden and tenacity of potential pathogens on surfaces and their transmission routes, influence of disinfecting surface cleaning on the rate of nosocomial infections, interruption of cross infections due to multidrug-resistant organisms, and outbreak control by disinfecting cleaning within bundles. The criteria for the selection of disinfectants are determined by the requirements for effectiveness, the efficacy spectrum, the compatibility for humans and the environment, as well as the risk potential for the development of tolerance and resistance. Detailed instructions on the organization and implementation of cleaning and disinfection measures, including structural and equipment requirements, serve as the basis for their implementation. Since the agents for surface disinfection and disinfecting surface cleaning have been classified as biocides in Europe since 2013, the regulatory consequences are explained. As possible addition to surface disinfection, probiotic cleaning, is pointed out. In an informative appendix (only in German), the pathogen characteristics for their acquisition of surfaces, such as tenacity, infectious dose and biofilm formation, and the toxicological and ecotoxicological characteristics of microbicidal agents as the basis for their selection are explained, and methods for the evaluation of the resulting quality of cleaning or disinfecting surface cleaning are presented.

Challenges and future opportunities to unlock the critical supply chain of personal and protective equipment (PPE) encompassing decontamination and reuse under emergency use authorization (EUA) conditions during the COVID-19 pandemic: Through a reflective circularity and sustainability lens

Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and the resulting coronavirus disease (COVID-19), was declared a public health emergency of global concern by the World Health Organization (WHO) in the early months of 2020. There was a marked lack of knowledge to inform national pandemic response plans encompassing appropriate disease mitigation and preparation strategies to constrain and manage COVID-19. For example, the top 16 "most cited" papers published at the start of the pandemic on core knowledge gaps collectively constitute a staggering 29,393 citations. Albeit complex, appropriate decontamination modalities have been reported and developed for safe reuse of personal and protective equipment (PPE) under emergency use authorization (EUA) where critical supply chain shortages occur for healthcare workers (HCWs) caused by the COVID-19 pandemic. Commensurately, these similar methods may provide solutions for the safe decontamination of enormous volumes of PPE waste promoting opportunities in the circular bioeconomy that will also protect our environment, habitats and natural capital. The co-circulation of the highly transmissive mix of COVID-19 variants of concern (VoC) will continue to challenge our embattled healthcare systems globally for many years to come with an emphasis placed on maintaining effective disease mitigation strategies. This viewpoint article addresses the rationale and key developments in this important area since the onset of the COVID-19 pandemic and provides an insight into a variety of potential opportunities to unlock the long-term sustainability of single-use medical devices, including waste management.

Organic pollutants degradation using plasma with simultaneous ammonification assisted by electrolytic two-cell system

Atmospheric non-thermal dielectric barrier discharge (DBD) plasma has gained considerable attention due to its cost-efficiency, environmental friendliness, and simplicity. However, certain deficiencies restrict its broad application. Herein, the DBD plasma was used to disrupt three model pharmaceutically active compounds (PhACs), sulfamethoxazole (SMX), ibuprofen (IBP), and norfloxacin (NFX), by varying parameters, such as gas type (Ar, N2, O2, and air) and flow rate (1-4 L min-1). The air plasma discharge had the highest degradation efficiency, and the air flow rate was optimized at 2 L min-1. However, only 10% of IBP was removed by the sole plasma, whereas NFX and SMX were entirely removed after 30 min. Since the air plasma discharge generates reactive oxygen and nitrogen species in a chained reaction, the remaining NO2- and NO3- in the aqueous phase were problematic. Therefore, by coupling plasma with electrolysis using Cu/reduced Cu nanowire (R-CuNw) as the anode/cathode, all three PhACs were removed within 30 min, and NO2- and NO3- were completely reduced to NH3 with cathodic reduction. Moreover, the electrical energy per order (EEO, 0.04 kWh L-1) and treatment cost (0.003 USD L-1) were much lower than those of the single system. This system demonstrates great potential for water remediation, and the production of NH3 as a value-added by-product remarkably improves its practicality and is of great importance in agriculture and energy-related industries.